Reactivating the IL-6/STAT3/ARF-dependent senescence pathway57 might be a promising strategy for PCa therapy via downregulation of Mdm2 (ref. 58) or p53 induction59. The gene discussed is STAT3; the disease is posterior cortical atrophy.